Group 1: Company Performance Overview - In the first half of 2024, the company's sales revenue from distribution and direct sales channels decreased by 5.19% and 11.62% year-on-year, respectively [2] - The decline in sales is attributed to high inventory levels of cold medicine in the market that need to be digested, leading to a downward trend in sales [2] - Key products such as Huoxiang Zhengqi Decoction experienced a sales drop due to lower-than-expected market demand, influenced by late summer heat in 2024 [2] Group 2: E-commerce Business Insights - The e-commerce segment consists of drug and non-drug categories, with the drug category showing stable growth and profit margins comparable to offline channels [3] - The non-drug category is in a rapid expansion phase, targeting a 100% annual growth rate, focusing on market share rather than immediate profitability [3] Group 3: Future Business Goals - The company aims to double its revenue and triple its net profit by 2027, targeting approximately 150 million yuan in profit [3] - Key strategies for achieving these goals include deepening existing market presence, increasing drug offerings, expanding non-drug e-commerce, and pursuing mergers and acquisitions [3] Group 4: Product Launch and Sales Channels - The company is prioritizing the relaunch of key products from Henan Xinxin, with several products expected to be launched between June and August 2025 [4] - Sales channels for Henan Xinxin products include distribution and direct sales at OTC terminals, with additional sales through community hospitals, clinics, and e-commerce platforms [4] Group 5: Shareholder Actions - The major shareholder's plan to increase shareholding is currently in progress, with the company committed to ensuring timely completion and disclosure of this plan [4]